Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 877


Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.


Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

Welch HG, Schwartz LM, Woloshin S.

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7.


National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.

Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE.

Cancer. 2014 May 15;120(10):1491-8. doi: 10.1002/cncr.28600. Epub 2014 Feb 12.


Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.

Welch HG, Fisher ES, Gottlieb DJ, Barry MJ.

J Natl Cancer Inst. 2007 Sep 19;99(18):1395-400. Epub 2007 Sep 11.


PSA screening among elderly men with limited life expectancies.

Walter LC, Bertenthal D, Lindquist K, Konety BR.

JAMA. 2006 Nov 15;296(19):2336-42.


Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.

Espaldon R, Kirby KA, Fung KZ, Hoffman RM, Powell AA, Freedland SJ, Walter LC.

Urology. 2014 Mar;83(3):599-605. doi: 10.1016/j.urology.2013.10.051. Epub 2014 Jan 16.


Prostate-specific antigen testing of older men.

Carter HB, Landis PK, Metter EJ, Fleisher LA, Pearson JD.

J Natl Cancer Inst. 1999 Oct 20;91(20):1733-7.


National evidence on the use of shared decision making in prostate-specific antigen screening.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN.

Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.


Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.

Varkarakis J, Pinggera GM, Sebe P, Berger A, Bartsch G, Horninger W.

Urology. 2004 Feb;63(2):337-41.


PSA-based screening for prostate cancer. Too many adverse effects.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):215-7. Review.


Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Welch HG, Albertsen PC.

J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. doi: 10.1093/jnci/djp278. Epub 2009 Aug 31.


Impact of age and comorbidity on colorectal cancer screening among older veterans.

Walter LC, Lindquist K, Nugent S, Schult T, Lee SJ, Casadei MA, Partin MR.

Ann Intern Med. 2009 Apr 7;150(7):465-73.


Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.

Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians.

Ann Intern Med. 2013 May 21;158(10):761-9. doi: 10.7326/0003-4819-158-10-201305210-00633.


Risks of PSA screening now better understood.

Peres J.

J Natl Cancer Inst. 2013 Nov 6;105(21):1590-2. doi: 10.1093/jnci/djt328. Epub 2013 Oct 18. No abstract available.


Prevalence of prostate specific antigen testing for prostate cancer in elderly men.

Dyche DJ, Ness J, West M, Allareddy V, Konety BR.

J Urol. 2006 Jun;175(6):2078-82.


Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.

Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ.

J Urol. 2005 Dec;174(6):2154-7, discussion 2157.


Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.


What happens after an elevated PSA test: the experience of 13,591 veterans.

Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW.

J Gen Intern Med. 2010 Nov;25(11):1205-10. doi: 10.1007/s11606-010-1468-9. Epub 2010 Aug 10.


Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.

Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1654-60. doi: 10.1111/j.1464-410X.2012.11481.x. Epub 2012 Oct 8.

Items per page

Supplemental Content

Write to the Help Desk